NextCure (NXTC) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NextCure (NXTC) has outperformed Quince Therapeutics (QNCX) over the past year, losing 1.0% versus a loss of 92.4%. Over five years, NXTC leads with a -93.5% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($33.9 million vs $30.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXTC | QNCX |
|---|---|---|
| Share price | $6.63 | $33.38 |
| Market cap | $30.33M | $33.94M |
| 1-day change | -2.29% | +13.68% |
| YTD return | -52.22% | -95.62% |
| 1-year return | -1.02% | -92.35% |
| 5-year return | -93.53% | -99.77% |
| EPS (TTM) | $-8.71 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $910.00 |
| 52-week low | $1.55 | $15.10 |
| Distance from 52-week high | -57.91% | -96.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +201.89% | +126.01% |
| Average volume | 2.11M | 28.83K |
| Shares outstanding | 4.58M | 1.02M |
| Employees | 40 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed QNCX by 91.3 percentage points over the past year.
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
NXTC vs QNCX FAQ
Which is bigger, NextCure or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $33.94M compared with $30.33M for NextCure (NXTC).
Which stock has performed better over the past year, NXTC or QNCX?
NXTC returned -1.02% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are NextCure and Quince Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for NextCure and Biotechnology: Biological Products (No Diagnostic Substances) for Quince Therapeutics.